We are monitoring the impact of COVID-19 on North America Cardiovascular Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date September, 2021
ID: 12182
Share on
Share on

North America Cardiovascular Drugs Market Research Report – Segmented By Drugs Type, Disease indication, End-Users and Country (United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026.

Pulished: September, 2021
ID: 12182
Pages: 100

North America Cardiovascular Drugs Market Size (2021 to 2026)

The North America Oncology Drugs Market was worth USD 31.85 Billion in 2021 and is estimated to be growing at a CAGR of 5.38%, to reach USD 41.40 Billion by 2026.

Cardiovascular drugs are agents that are used to treat diseases associated with the circulatory system, including blood clots, stroke, coronary heart disease, hypertension/ hypotension, arrhythmias, high cholesterol, and heart failure.

The North America cardiovascular drugs market is projected to be fuelled by the Increased awareness of cardiovascular health, increase in product introductions in technological healthcare sectors. Cardiovascular therapy entails a multifaceted strategy that may necessitate the use of a variety of drugs.

Other significant driving factors in the market include a growth in the incidence of cardiovascular diseases and a growing need for more effective medicines. In addition, cardiovascular treatments have advanced significantly in research and development since they were first made available to the general public.

On the other hand, the major factors contributing to the growth are sedentary lifestyles with little physical activity, a poor diet, anxiety, and stress, all of which lead to chronic diseases such as diabetes and obesity, as well as an increase in the prevalence of multiple cardiovascular diseases such as CAD, strokes, and atrial fibrillation, necessitating effective CVD treatment.

In the recent period, there has been a significant increase in the number of innovative treatments introduced to the market and proven to be quite successful. 

Moreover, with the presence of multiple significant firms and the growing effect of comparatively cheaper generics, the cardiovascular medication market may be considered cluttered. 

However, the nature of cardiovascular disorders makes them essentially incurable, and the increased prevalence is making therapy even more difficult for patients. This resulted in the emergence of a significant unmet treatment requirement in the market, which is expected to be one of the market’s other important driving factors.

The increased frequency of various coronary heart disorders such as stroke and cardiomyopathy, which causes a high number of cardiac deaths and favorable reimbursement schemes, are the primary reasons driving the growth of the North America cardiovascular drugs market.

Several influential market leaders have introduced innovative medications to address the wide range of cardiovascular disease treatment needs. This leads the cardiovascular drugs market.

However, The market is restrained by a decreasing target population and growing medication research costs. Despite the high frequency of cardiovascular illnesses, drug development pipelines have steadily declined for several reasons.

This research report on the North America cardiovascular drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Antihypertensive
  • Antihyperlipidemic
  • Anticoagulants
  • Antiplatelet Drugs
  • Others

By Disease Indication:

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Arrhythmia
  • Others

By End-Users:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Country:

  • United States
  • Canada
  • Rest of North America

The North America cardiovascular drugs market is expected to dominate the entire market throughout the forecast period. This is due to the increased awareness of various heart diseases in the area. In addition, the technological advancements in the healthcare sectors, increasing healthcare spending, and favorable reimbursement policies are contributing to the market growth. According to the Global Health and Wellness Report issued, approximately 40% of the adult population in the United States was diagnosed with a cardiovascular problem, resulting in an increased demand for highly effective and immediate treatment. The United States is the largest market for cardiovascular drugs, followed by Canada in North America.

The U.S. held the largest share of the cardiovascular market, and it is anticipated to continue its growth during the forecast period. The major factors contributing to the growth are sedentary lifestyles with little physical activity, a poor diet, anxiety, and stress, all of which lead to chronic diseases like diabetes and obesity, as well as an increase in the prevalence of multiple cardiovascular diseases such as CAD, strokes, and atrial fibrillation in the United States, necessitating effective CVD treatment.

According to the American Heart Association, nearly 92.1 million people in the United States suffered from cardiovascular diseases in 2018, with coronary artery disease (CAD) being the leading cause of death. This increased demand for better treatment with effective medication driving the market in the United States, which contributed to the market’s outstanding revenue share propelling the North America cardiovascular drugs market.

KEY MARKET PLAYERS:

Merck & Co, Sanofi S.A., Pfizer Inc., Bristol-Myers Squibb Company, and Novartis AG are a few of the noteworthy companies operating in the North America cardiovascular drugs market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 North America Cardiovascular Drugs Market – By Drug Type:                

                        6.1.1  Antihypertensive         

                        6.1.2 Antihyperlipidemic       

                        6.1.3 Anticoagulants  

                        6.1.4 Antiplatelet Drugs        

                        6.1.5    Others

                        6.1.6 Market Size Estimations & Forecasts (2021-2026)      

                        6.1.7 Y-o-Y Growth Rate Analysis      

                        6.1.8 Market Attractiveness Index    

            6.2 North America Cardiovascular Drugs Market – By Disease Indication:               

                        6.2.1    Hypertension 

                        6.2.2      Hyperlipidaemia       

                        6.2.3 Coronary Artery Disease           

                        6.2.4 Arrhythmia       

                        6.2.5 Others   

                        6.2.6 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.7 Y-o-Y Growth Rate Analysis      

                        6.2.8 Market Attractiveness Index    

            6.3 North America Cardiovascular Drugs Market – By End-Users:                

                        6.3.1 Hospital Pharmacies     

                        6.3.2  Retail Pharmacies        

                        6.3.3 Online Pharmacies        

                        6.3.4    Others

                        6.3.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.6 Y-o-Y Growth Rate Analysis      

                        6.3.7 Market Attractiveness Index    

7. Geographical Landscape                            

            7.1 North America - Market Analysis (2021 - 2026)              

                        7.1.1 By Country        

                                    7.1.1.1 USA

                                    7.1.1.2 Canada

                        7.1.2 By Drug Type:   

                        7.1.3 By Disease Indication:  

                        7.1.4 By End-Users:    

8. Key Player Analysis                        

            8.1 Merck & Co                      

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Sanofi S.A.            

            8.3 Pfizer Inc.             

            8.4 Bristol-Myers Squibb Company               

            8.5 Novartis AG                      

9. Market Outlook & Investment Opportunities                               

10.Appendix                           

            List of Tables              

            List of Figures  

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of drug type, disease indication, end-users, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. North America Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  2. North America Antihypertensive Market By Region, From 2021 to 2026 ( USD Billion )

  3. North America Antihyperlipidemic Market By Region, From 2021 to 2026 ( USD Billion )

  4. North America Anticoagulants Market By Region, From 2021 to 2026 ( USD Billion )

  5. North America   Antiplatelet Drugs Market By Region, From 2021 to 2026 ( USD Billion )

  6. North America Others Market By Region, From 2021 to 2026 ( USD Billion )

  7. North America Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  8. North America Hypertension Market By Region, From 2021 to 2026 ( USD Billion )

  9. North America Hyperlipidaemia Market By Region, From 2021 to 2026 ( USD Billion )

  10. North America  Coronary Artery Disease Market By Region, From 2021 to 2026 ( USD Billion )

  11. North America   Arrhythmia Market By Region, From 2021 to 2026 ( USD Billion )

  12. North America   Others Market By Region, From 2021 to 2026 ( USD Billion )

  13. North America Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

  14. North America  Hospital Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  15. North America Retail Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  16. North America    Online Pharmacies Market By Region, From 2021 to 2026 ( USD Billion )

  17. North America Others Market By Region, From 2021 to 2026 ( USD Billion )

  18. United States Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  19. United States Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  20. United States Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion )

  21. Canada Cardiovascular Drugs Market By Drug Type, From 2021 to 2026 ( USD Billion )

  22. Canada Cardiovascular Drugs Market By Disease Indication, From 2021 to 2026 ( USD Billion )

  23. Canada Cardiovascular Drugs Market By End-Users, From 2021 to 2026 ( USD Billion ).

 

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample